1
|
Rodnick ME, Sollert C, Parr DC, Frigell J, Gagnon K, Scott PJH. Preparation of [ 68Ga]GaCl 3 Using a Cyclotron. Methods Mol Biol 2024; 2729:55-64. [PMID: 38006491 DOI: 10.1007/978-1-0716-3499-8_5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2023]
Abstract
Recent developments in 68Ga-radiopharmaceuticals, including a number of regulatory approvals for clinical use, has created a hitherto unprecedented demand for 68Ga. Reliable access to enough 68Ga to meet growing clinical demand using only 68Ge/68Ga generators has been problematic in recent years. To address this challenge, we have optimized the direct production of 68Ga on a cyclotron via the 68Zn(p,n)68Ga reaction using a liquid target. This protocol describes the cyclotron-based production of [68Ga]GaCl3 implemented at the University of Michigan using a liquid target on GE PETtrace instrumentation. The protocol provides 56 ± 4 mCi (n = 3) of [68Ga]GaCl3 that meets the necessary quality control criteria to use for the preparation of 68Ga-radiopharmaceuticals for human use.
Collapse
Affiliation(s)
| | | | | | - Jens Frigell
- GE Healthcare, GEMS PET Systems, Uppsala, Sweden
| | | | - Peter J H Scott
- Department of Radiology, University of Michigan, Ann Arbor, MI, USA
| |
Collapse
|
2
|
Mou L, De Dominicis L, Cisternino S, Skliarova H, Campostrini M, Rigato V, De Nardo L, Meléndez-Alafort L, Esposito J, Haddad F, Pupillo G. Nuclear Cross-Section of Proton-Induced Reactions on Enriched 48Ti Targets for the Production of Theranostic 47Sc Radionuclide, 46cSc, 44mSc, 44gSc, 43Sc, and 48V. Pharmaceuticals (Basel) 2023; 17:26. [PMID: 38256860 PMCID: PMC10819312 DOI: 10.3390/ph17010026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 12/12/2023] [Accepted: 12/21/2023] [Indexed: 01/24/2024] Open
Abstract
The cross-sections of the 48Ti(p,x)47Sc, 46cSc, 44mSc, 44gSc, 43Sc, and 48V nuclear reactions were measured from 18 to 70 MeV, with particular attention to 47Sc production. Enriched 48Ti powder was deposited on an aluminum backing and the obtained targets were characterized via elastic backscattering spectroscopy at the INFN-LNL. Targets were exposed to low-intensity proton irradiation using the stacked-foils technique at the ARRONAX facility. Activated samples were measured using γ-spectrometry; the results were compared with the data int he literature and the theoretical TALYS-based values. A regular trend in the new values obtained from the different irradiation runs was noted, as well as a good agreement with the literature data, for all the radionuclides of interest: 47Sc, 46cSc, 44mSc, 44gSc, 43Sc, and 48V. 47Sc production was also discussed, considering yield and radionuclidic purity, for different 47Sc production scenarios.
Collapse
Affiliation(s)
- Liliana Mou
- Laboratori Nazionali di Legnaro (INFN-LNL), Istituto Nazionale di Fisica Nucleare, Viale dell’Università 2, Legnaro, 35020 Padova, Italy; (L.M.); (S.C.); (M.C.); (V.R.); (J.E.)
| | - Lucia De Dominicis
- Laboratori Nazionali di Legnaro (INFN-LNL), Istituto Nazionale di Fisica Nucleare, Viale dell’Università 2, Legnaro, 35020 Padova, Italy; (L.M.); (S.C.); (M.C.); (V.R.); (J.E.)
- Dipartimento di Fisica e Astronomia Galileo Galilei, Università degli Studi di Padova, Via F. Marzolo 8, 35131 Padova, Italy;
| | - Sara Cisternino
- Laboratori Nazionali di Legnaro (INFN-LNL), Istituto Nazionale di Fisica Nucleare, Viale dell’Università 2, Legnaro, 35020 Padova, Italy; (L.M.); (S.C.); (M.C.); (V.R.); (J.E.)
| | - Hanna Skliarova
- INFN, Sezione di Padova (INFN-PD), Via F. Marzolo 8, 35131 Padova, Italy;
| | - Matteo Campostrini
- Laboratori Nazionali di Legnaro (INFN-LNL), Istituto Nazionale di Fisica Nucleare, Viale dell’Università 2, Legnaro, 35020 Padova, Italy; (L.M.); (S.C.); (M.C.); (V.R.); (J.E.)
| | - Valentino Rigato
- Laboratori Nazionali di Legnaro (INFN-LNL), Istituto Nazionale di Fisica Nucleare, Viale dell’Università 2, Legnaro, 35020 Padova, Italy; (L.M.); (S.C.); (M.C.); (V.R.); (J.E.)
| | - Laura De Nardo
- Dipartimento di Fisica e Astronomia Galileo Galilei, Università degli Studi di Padova, Via F. Marzolo 8, 35131 Padova, Italy;
- INFN, Sezione di Padova (INFN-PD), Via F. Marzolo 8, 35131 Padova, Italy;
| | | | - Juan Esposito
- Laboratori Nazionali di Legnaro (INFN-LNL), Istituto Nazionale di Fisica Nucleare, Viale dell’Università 2, Legnaro, 35020 Padova, Italy; (L.M.); (S.C.); (M.C.); (V.R.); (J.E.)
| | - Férid Haddad
- GIP ARRONAX, 1 Rue Aronnax, 44817 Saint Herblain, France;
- Laboratoire Subatech, IN2P3-CNRS, IMT Atlantique, Nantes Université, 4 Rue Alfred Kastler, 44307 Nantes, France
| | - Gaia Pupillo
- Laboratori Nazionali di Legnaro (INFN-LNL), Istituto Nazionale di Fisica Nucleare, Viale dell’Università 2, Legnaro, 35020 Padova, Italy; (L.M.); (S.C.); (M.C.); (V.R.); (J.E.)
| |
Collapse
|
3
|
Juget F, van Dijk M, Maugeri EA, Schumann MD, Heinitz S, Boyarsky A, Köster U, Shchutska L, Bailat C. Measurement of the 171Tm beta spectrum. Appl Radiat Isot 2023; 202:111058. [PMID: 37797449 DOI: 10.1016/j.apradiso.2023.111058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 09/24/2023] [Accepted: 09/26/2023] [Indexed: 10/07/2023]
Abstract
The beta spectrum of the main transition of the β- decay of 171Tm was measured using a double focalizing spectrometer. The instrument was lately improved in order to reduce its low energy threshold to 34 keV. We used the spectrometer to measure the beta spectrum end-point energy of the main transition of 171Tm decay using the Kurie plot formalism. We report a new value of 97.60(38) keV, which is in agreement with previous measurements. In addition, the spectrum shape was compared with the ξ-approximation calculation where the shape factor is equal to 1 and good agreement was found between the theory and the measurement at the 1% level.
Collapse
Affiliation(s)
| | - Maarten van Dijk
- Laboratoire de Physique des Hautes Energies, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | | | | | | | - Alexey Boyarsky
- Laboratoire de Physique des Hautes Energies, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Instituut Lorentz, Leiden University, Leiden, the Netherlands
| | | | - Lesya Shchutska
- Laboratoire de Physique des Hautes Energies, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Claude Bailat
- Institute of Radiation Physics, Lausanne, Switzerland
| |
Collapse
|
4
|
Moiseeva AN, Makoveeva KA, Furkina EB, Artyushova EV, German MN, Khomenko IA, Konevega AL, Kormazeva ES, Novikov VI, Aksenov NV, Gustova NS, Aliev RA. Co-production of 155Tb and 152Tb irradiating 155Gd / 151Eu tandem target with a medium energy α-particle beam. Nucl Med Biol 2023; 126-127:108389. [PMID: 37783103 DOI: 10.1016/j.nucmedbio.2023.108389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Revised: 07/27/2023] [Accepted: 09/25/2023] [Indexed: 10/04/2023]
Abstract
INTRODUCTION Four terbium isotopes 149,152,155,161Tb emitting various types of radiation can be used for both diagnostics and therapy. 152Tb emits positrons and is ideal for PET. 155Tb is considered a promising Auger emitter and a diagnostic pair for other terbium therapeutic isotopes. Several methods for the production of 155Tb using charged particle accelerators have been proposed, but they all have significant limitations. The restricted availability of this isotope hinders its medical applications. We have proposed a new method for production of 155Tb, irradiating enriched 155Gd by alpha particles. The possibility of simultaneous production of two isotopes of terbium, 152,155Tb, was also studied for more efficient cyclotron beam use. METHODS Irradiation of 155Gd enriched targets and 155Gd / 151Eu tandem target with alpha-particles with an energy of 54 MeV was carried out at the U-150 cyclotron at the NRC "Kurchatov Institute". The cross sections of nuclear reactions on enr-155Gd were measured by the stack foil technique, detecting the gamma-radiation of the activation products. The separation of rare earth elements was performed by extraction chromatography with the LN Resin. 155Tb was produced via 155Dy decay. RESULTS The cross sections for the 155,156Tb and 155,157Dy production were measured by the irradiation of a gadolinium target enriched with the 155Gd isotope with alpha-particles in an energy range of 54 → 33 MeV. The yield of 155Dy on a thick target at 54 MeV was 130 MBq/μAh, which makes it possible to obtain 1 GBq of 155Tb in 11 hour-irradiation with 20 μA beam current. The possibility of simultaneous production of 152,155Tb by irradiation of 155Gd and 151Eu tandem target with medium-energy alpha-particles is implemented. Optimal irradiation energy ranges of alpha -particles as 54 → 42 MeV for 155Tb and 42 → 34 MeV for 152Tb were suggested. Product activity and radionuclidic purity were calculated.
Collapse
Affiliation(s)
- A N Moiseeva
- National Research Center "Kurchatov Institute", Russia.
| | - K A Makoveeva
- National Research Center "Kurchatov Institute", Russia
| | - E B Furkina
- National Research Center "Kurchatov Institute", Russia
| | | | - M N German
- National Research Center "Kurchatov Institute", Russia
| | - I A Khomenko
- National Research Center "Kurchatov Institute", Russia
| | - A L Konevega
- National Research Center "Kurchatov Institute", Russia
| | - E S Kormazeva
- National Research Center "Kurchatov Institute", Russia
| | - V I Novikov
- National Research Center "Kurchatov Institute", Russia
| | - N V Aksenov
- Flerov Laboratory of Nuclear Reactions, Joint Institute for Nuclear Research, Russia
| | - N S Gustova
- Flerov Laboratory of Nuclear Reactions, Joint Institute for Nuclear Research, Russia
| | - R A Aliev
- National Research Center "Kurchatov Institute", Russia
| |
Collapse
|
5
|
Wang Y, Sounalet T, Guertin A, Nigron E, Michel N, Haddad F. Study of terbium production from enriched Gd targets via the reaction 155Gd(d,2n) 155Tb. Appl Radiat Isot 2023; 201:110996. [PMID: 37657224 DOI: 10.1016/j.apradiso.2023.110996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 08/02/2023] [Accepted: 08/21/2023] [Indexed: 09/03/2023]
Abstract
The terbium (Tb) family has attracted much attention in recent years thanks to the diagnostic and therapeutic applications of the quadruplet 149Tb, 152Tb, 155Tb and 161Tb. However, the scarce availability of Tb radioisotopes is one of the main reasons hindering its clinical applications. To increase its availability, this work proposes to use enriched gadolinium (Gd) targets to produce some Tb radioisotopes (149Tb, 152Tb, and 155Tb) via deuteron-induced reactions in cyclotrons. The production of the Auger and gamma emitter 155Tb was chosen as a case study because the 155Gd enrichment (92.8%) is the highest available from all Gd stable isotopes. The involved reaction is 155Gd(d,2n)155Tb. Using enriched thin Gd-containing targets, cross-sections of the reactions 155Gd(d,x)153,154,155,156Tb have been measured at the GIP ARRONAX cyclotron facility with a beam energy ranging from 8 MeV to 30 MeV. This measurement allows for estimating the production yield and the purity of 155Tb, and for determining the irradiation parameters for large production batches. A thick enriched 155Gd2O3 target has been then irradiated with an incident energy of 15.1 MeV and a beam current of 368 nA for 1 h. The production yield of 155Tb is 10.2 MBq/μA/h at End Of Bombardment (EOB) and the purity is 89% after 14 days of decay. These experimental values are consistent with estimation based on measured cross-sections. A comparison of the deuteron-induced and proton-induced production routes is also presented in this paper.
Collapse
Affiliation(s)
- Yizheng Wang
- Subatech, UMR 6457, IMT Atlantique, CNRS/IN2P3, Nantes Université, 4 rue Alfred Kastler BP20722, 44307, Nantes, Cedex 3, France.
| | - Thomas Sounalet
- Subatech, UMR 6457, IMT Atlantique, CNRS/IN2P3, Nantes Université, 4 rue Alfred Kastler BP20722, 44307, Nantes, Cedex 3, France
| | - Arnaud Guertin
- Subatech, UMR 6457, IMT Atlantique, CNRS/IN2P3, Nantes Université, 4 rue Alfred Kastler BP20722, 44307, Nantes, Cedex 3, France
| | - Etienne Nigron
- GIP ARRONAX, 1 rue Aronnax, CS10112, 44817, Saint-Herblain, Cedex, France
| | - Nathalie Michel
- Subatech, UMR 6457, IMT Atlantique, CNRS/IN2P3, Nantes Université, 4 rue Alfred Kastler BP20722, 44307, Nantes, Cedex 3, France; GIP ARRONAX, 1 rue Aronnax, CS10112, 44817, Saint-Herblain, Cedex, France
| | - Férid Haddad
- Subatech, UMR 6457, IMT Atlantique, CNRS/IN2P3, Nantes Université, 4 rue Alfred Kastler BP20722, 44307, Nantes, Cedex 3, France; GIP ARRONAX, 1 rue Aronnax, CS10112, 44817, Saint-Herblain, Cedex, France
| |
Collapse
|
6
|
Morgan KA, Rudd SE, Noor A, Donnelly PS. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides. Chem Rev 2023; 123:12004-12035. [PMID: 37796539 DOI: 10.1021/acs.chemrev.3c00456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023]
Abstract
Molecular changes in malignant tissue can lead to an increase in the expression levels of various proteins or receptors that can be used to target the disease. In oncology, diagnostic imaging and radiotherapy of tumors is possible by attaching an appropriate radionuclide to molecules that selectively bind to these target proteins. The term "theranostics" describes the use of a diagnostic tool to predict the efficacy of a therapeutic option. Molecules radiolabeled with γ-emitting or β+-emitting radionuclides can be used for diagnostic imaging using single photon emission computed tomography or positron emission tomography. Radionuclide therapy of disease sites is possible with either α-, β-, or Auger-emitting radionuclides that induce irreversible damage to DNA. This Focus Review centers on the chemistry of theranostic approaches using metal radionuclides for imaging and therapy. The use of tracers that contain β+-emitting gallium-68 and β-emitting lutetium-177 will be discussed in the context of agents in clinical use for the diagnostic imaging and therapy of neuroendocrine tumors and prostate cancer. A particular emphasis is then placed on the chemistry involved in the development of theranostic approaches that use copper-64 for imaging and copper-67 for therapy with functionalized sarcophagine cage amine ligands. Targeted therapy with radionuclides that emit α particles has potential to be of particular use in late-stage disease where there are limited options, and the role of actinium-225 and lead-212 in this area is also discussed. Finally, we highlight the challenges that impede further adoption of radiotheranostic concepts while highlighting exciting opportunities and prospects.
Collapse
Affiliation(s)
- Katherine A Morgan
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Melbourne 3010, Australia
| | - Stacey E Rudd
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Melbourne 3010, Australia
| | - Asif Noor
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Melbourne 3010, Australia
| | - Paul S Donnelly
- School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Melbourne 3010, Australia
| |
Collapse
|
7
|
Hussain M, Qaim SM, Spahn I, Aslam MN, Neumaier B. Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review. Front Chem 2023; 11:1270351. [PMID: 37841203 PMCID: PMC10570421 DOI: 10.3389/fchem.2023.1270351] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Accepted: 09/08/2023] [Indexed: 10/17/2023] Open
Abstract
Copper has several clinically relevant radioisotopes and versatile coordination chemistry, allowing attachment of its radionuclides to biological molecules. This characteristic makes it suitable for applications in molecular imaging or radionuclide targeted therapy. Of particular interest in nuclear medicine today is the theranostic approach. This brief review considers five radionuclides of copper. These are Cu-60, Cu-61, Cu-62, Cu-64, and Cu-67. The first four are positron emitters for imaging, and the last one Cu-67 is a β--emitting radionuclide suitable for targeted therapy. The emphasis here is on theory-aided evaluation of available experimental data with a view to establishing standardised cross-section database for production of the relevant radionuclide in high purity. Evaluated cross section data of the positron emitters have been already extensively reported; so here they are only briefly reviewed. More attention is given to the data of the 68Zn(p,2p)67Cu intermediate energy reaction which is rather commonly used for production of 67Cu.
Collapse
Affiliation(s)
- Mazhar Hussain
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich (FZJ), Jülich, Germany
- Department of Physics, Government College University Lahore (GCUL), Lahore, Pakistan
| | - Syed M. Qaim
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich (FZJ), Jülich, Germany
| | - Ingo Spahn
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich (FZJ), Jülich, Germany
| | - M. Naveed Aslam
- Department of Physics, COMSATS University Islamabad, Lahore, Pakistan
| | - Bernd Neumaier
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich (FZJ), Jülich, Germany
| |
Collapse
|
8
|
Zoi V, Giannakopoulou M, Alexiou GA, Bouziotis P, Thalasselis S, Tzakos AG, Fotopoulos A, Papadopoulos AN, Kyritsis AP, Sioka C. Nuclear Medicine and Cancer Theragnostics: Basic Concepts. Diagnostics (Basel) 2023; 13:3064. [PMID: 37835806 PMCID: PMC10572920 DOI: 10.3390/diagnostics13193064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Revised: 09/23/2023] [Accepted: 09/25/2023] [Indexed: 10/15/2023] Open
Abstract
Cancer theragnostics is a novel approach that combines diagnostic imaging and radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized for positron emission tomography imaging through linkage to a proper radionuclide, and the other bearing an alpha- or beta-emitter isotope that can induce significant damage to cancer cells. In recent years, the use of theragnostics in nuclear medicine clinical practice has increased considerably, and thus investigation has focused on the identification of novel radionuclides that can bind to molecular targets that are typically dysregulated in different cancers. The major advantages of the theragnostic approach include the elimination of multi-step procedures, reduced adverse effects to normal tissues, early diagnosis, better predictive responses, and personalized patient care. This review aims to discuss emerging theragnostic molecules that have been investigated in a series of human malignancies, including gliomas, thyroid cancer, neuroendocrine tumors, cholangiocarcinoma, and prostate cancer, as well as potent and recently introduced molecular targets, like cell-surface receptors, kinases, and cell adhesion proteins. Furthermore, special reference has been made to copper radionuclides as theragnostic agents and their radiopharmaceutical applications since they present promising alternatives to the well-studied gallium-68 and lutetium-177.
Collapse
Affiliation(s)
- Vasiliki Zoi
- Neurosurgical Institute, University of Ioannina, 45110 Ioannina, Greece
| | | | - George A. Alexiou
- Neurosurgical Institute, University of Ioannina, 45110 Ioannina, Greece
- Department of Neurosurgery, University of Ioannina, 45110 Ioannina, Greece
| | - Penelope Bouziotis
- Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece;
| | | | - Andreas G. Tzakos
- Department of Chemistry, Section of Organic Chemistry and Biochemistry, University of Ioannina, 45110 Ioannina, Greece
| | | | | | | | - Chrissa Sioka
- Neurosurgical Institute, University of Ioannina, 45110 Ioannina, Greece
- Department of Nuclear Medicine, University of Ioannina, 45110 Ioannina, Greece
| |
Collapse
|
9
|
Laurène W, Raúl L, Katalin S, Céline F, Gilles K, Antonio M, Charlotte C, Samir A. Design and synthesis of a new bifunctional chelating agent: Application for Al 18F/ 177Lu complexation. J Inorg Biochem 2023; 246:112267. [PMID: 37329775 DOI: 10.1016/j.jinorgbio.2023.112267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 05/09/2023] [Accepted: 05/23/2023] [Indexed: 06/19/2023]
Abstract
Theranostic and personalized medicine are blooming strategies to improve oncologic patients' health care and facilitate early treatment. While 18F-radiochemistry for theranostic application is attractive due to its imaging properties, combining diagnosis by positron emission tomography (PET) via aluminum-fluoride-18 and β- therapy with lutetium-177 is relevant. Nevertheless, it requires the use of two different chelating agents, which are NOTA and DOTA for aluminum-fluoride-18 and lutetium-177 radiolabeling, respectively. To overcome this issue, we propose herein the synthesis of a new hybrid chelating agent named NO2A-AHM, which can be labeled with different types of emitters (β+, β- and γ) using the mismatched Al18F/177Lu pair. NO2A-AHM, is based on a hydrazine moiety functionalized by a NOTA cycle, a chelating arm, and a linker with a maleimide function. This design is chosen to increase the flexibility and allow the formation of 5 up to 7 coordination bonds with metal ions. Moreover, this agent can be coupled to targeting moieties containing a thiol function, such as peptides, to increase selectivity towards specific cancer cells. Experimental complexation and computational chemistry studies are performed to confirm the capacity of our chelating agent to label both aluminum-fluoride and lutetium using molecular modeling approaches at Density Functional Theory (DFT) level. The proof of concept of the ability of NO2A-AHM to complex both aluminum-fluoride-18, for PET imaging applications, and lutetium-177 for radiotherapy has shown encouraging results which is prominent for the development of a fully consistent theranostic approach.
Collapse
Affiliation(s)
- Wagner Laurène
- Université de Lorraine, CNRS, LCPM, F-54000 Nancy, France; Nancyclotep, Plateforme d'imagerie moléculaire, F-54511 Vandœuvre-lès-Nancy, France
| | - Losantos Raúl
- Université Paris Cité, CNRS, ITODYS, F-75006 Paris, France; Department of Chemistry, CISQ, Universidad de La Rioja, 26004 Logroño, Spain
| | | | - Frochot Céline
- Université de Lorraine, CNRS, LRGP, F-54000 Nancy, France
| | - Karcher Gilles
- Nancyclotep, Plateforme d'imagerie moléculaire, F-54511 Vandœuvre-lès-Nancy, France
| | - Monari Antonio
- Université Paris Cité, CNRS, ITODYS, F-75006 Paris, France
| | - Collet Charlotte
- Nancyclotep, Plateforme d'imagerie moléculaire, F-54511 Vandœuvre-lès-Nancy, France; Université de Lorraine, INSERM, IADI, F-54000 Nancy, France.
| | - Acherar Samir
- Université de Lorraine, CNRS, LCPM, F-54000 Nancy, France.
| |
Collapse
|
10
|
Krasnovskaya OO, Abramchuck D, Erofeev A, Gorelkin P, Kuznetsov A, Shemukhin A, Beloglazkina EK. Recent Advances in 64Cu/ 67Cu-Based Radiopharmaceuticals. Int J Mol Sci 2023; 24:ijms24119154. [PMID: 37298101 DOI: 10.3390/ijms24119154] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2023] [Revised: 05/19/2023] [Accepted: 05/21/2023] [Indexed: 06/12/2023] Open
Abstract
Copper-64 (T1/2 = 12.7 h) is a positron and beta-emitting isotope, with decay characteristics suitable for both positron emission tomography (PET) imaging and radiotherapy of cancer. Copper-67 (T1/2 = 61.8 h) is a beta and gamma emitter, appropriate for radiotherapy β-energy and with a half-life suitable for single-photon emission computed tomography (SPECT) imaging. The chemical identities of 64Cu and 67Cu isotopes allow for convenient use of the same chelating molecules for sequential PET imaging and radiotherapy. A recent breakthrough in 67Cu production opened previously unavailable opportunities for a reliable source of 67Cu with high specific activity and purity. These new opportunities have reignited interest in the use of copper-containing radiopharmaceuticals for the therapy, diagnosis, and theranostics of various diseases. Herein, we summarize recent (2018-2023) advances in the use of copper-based radiopharmaceuticals for PET, SPECT imaging, radiotherapy, and radioimmunotherapy.
Collapse
Affiliation(s)
- Olga O Krasnovskaya
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, 1/3, 119991 Moscow, Russia
| | - Daniil Abramchuck
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, 1/3, 119991 Moscow, Russia
| | - Alexander Erofeev
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, 1/3, 119991 Moscow, Russia
- Research Laboratory of Biophysics, National University of Science and Technology (MISIS), Leninskiy Prospect 4, 119049 Moscow, Russia
| | - Peter Gorelkin
- Research Laboratory of Biophysics, National University of Science and Technology (MISIS), Leninskiy Prospect 4, 119049 Moscow, Russia
| | - Alexander Kuznetsov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Leninskie Gory, 1, Bld. 2, 119991 Moscow, Russia
- Department of Physics, Lomonosov Moscow State University, Leninskie Gory, 1/2, 119991 Moscow, Russia
| | - Andrey Shemukhin
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Leninskie Gory, 1, Bld. 2, 119991 Moscow, Russia
| | - Elena K Beloglazkina
- Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, 1/3, 119991 Moscow, Russia
| |
Collapse
|
11
|
Mues Genannt Koers L, McNeil SW, Radchenko V, Paulssen E, Hoehr C. Production of Co-58m in a siphon-style liquid target on a medical cyclotron. Appl Radiat Isot 2023; 195:110734. [PMID: 36863263 DOI: 10.1016/j.apradiso.2023.110734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Revised: 02/06/2023] [Accepted: 02/17/2023] [Indexed: 02/27/2023]
Abstract
We present the production of 58mCo on a small, 13 MeV medical cyclotron utilizing a siphon style liquid target system. Different concentrated iron(III)-nitrate solutions of natural isotopic distribution were irradiated at varying initial pressures and subsequently separated by solid phase extraction chromatography. The radio cobalt (58m/gCo and 56Co) was successfully produced with saturation activities of (0.35 ± 0.03) MBq μA-1 for 58mCo with a separation recovery of (75 ± 2) % of cobalt after one separation step utilizing LN-resin.
Collapse
Affiliation(s)
- L Mues Genannt Koers
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T2A3, Canada; Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia, V6T 1Z1, Canada
| | - S W McNeil
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T2A3, Canada
| | - V Radchenko
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T2A3, Canada; Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia, V6T 1Z1, Canada
| | - E Paulssen
- Department of Chemistry and Biotechnology, FH Aachen - University of Applied Sciences, Heinrich-Mußmann-Straße 1, Germany; Delft University of Technology, Department Radiation Science and Technology, Mekelweg 15, 2629JB Delft, the Netherlands
| | - C Hoehr
- Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T2A3, Canada; Department of Physics and Astronomy, University of Victoria, 3800 Finnerty Road, Victoria, British Columbia, V8P 5C2, Canada; Department of Computer Science, Mathematics, Physics and Statistics, University of British Columbia Okanagan, 3187 University Way, Kelowna, British Columbia, V1V 1V7, Canada.
| |
Collapse
|
12
|
Radiochemistry with {Al18F}2+: Current status and optimization perspectives for efficient radiofluorination by complexation. Coord Chem Rev 2023. [DOI: 10.1016/j.ccr.2023.215028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
13
|
Benfante V, Stefano A, Ali M, Laudicella R, Arancio W, Cucchiara A, Caruso F, Cammarata FP, Coronnello C, Russo G, Miele M, Vieni A, Tuttolomondo A, Yezzi A, Comelli A. An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics. Diagnostics (Basel) 2023; 13:diagnostics13071210. [PMID: 37046428 PMCID: PMC10093267 DOI: 10.3390/diagnostics13071210] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2023] [Revised: 03/11/2023] [Accepted: 03/17/2023] [Indexed: 04/14/2023] Open
Abstract
Radionuclides are unstable isotopes that mainly emit alpha (α), beta (β) or gamma (γ) radiation through radiation decay. Therefore, they are used in the biomedical field to label biomolecules or drugs for diagnostic imaging applications, such as positron emission tomography (PET) and/or single-photon emission computed tomography (SPECT). A growing field of research is the development of new radiopharmaceuticals for use in cancer treatments. Preclinical studies are the gold standard for translational research. Specifically, in vitro radiopharmaceutical studies are based on the use of radiopharmaceuticals directly on cells. To date, radiometric β- and γ-counters are the only tools able to assess a preclinical in vitro assay with the aim of estimating uptake, retention, and release parameters, including time- and dose-dependent cytotoxicity and kinetic parameters. This review has been designed for researchers, such as biologists and biotechnologists, who would like to approach the radiobiology field and conduct in vitro assays for cellular radioactivity evaluations using radiometric counters. To demonstrate the importance of in vitro radiopharmaceutical assays using radiometric counters with a view to radiogenomics, many studies based on 64Cu-, 68Ga-, 125I-, and 99mTc-labeled radiopharmaceuticals have been revised and summarized in this manuscript.
Collapse
Affiliation(s)
- Viviana Benfante
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Molecular and Clinical Medicine, University of Palermo, 90127 Palermo, Italy
- Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), 90015 Cefalù, Italy
| | - Alessandro Stefano
- Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), 90015 Cefalù, Italy
| | - Muhammad Ali
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Molecular and Clinical Medicine, University of Palermo, 90127 Palermo, Italy
| | | | - Walter Arancio
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
| | - Antonino Cucchiara
- Department of Diagnostic and Therapeutic Services, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Via Tricomi 5, 90127 Palermo, Italy
| | - Fabio Caruso
- Department of Diagnostic and Therapeutic Services, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Via Tricomi 5, 90127 Palermo, Italy
| | - Francesco Paolo Cammarata
- Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), 90015 Cefalù, Italy
| | - Claudia Coronnello
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
- National Biodiversity Future Center (NBFC), 90133 Palermo, Italy
| | - Giorgio Russo
- Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), 90015 Cefalù, Italy
- National Biodiversity Future Center (NBFC), 90133 Palermo, Italy
| | - Monica Miele
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
| | - Alessandra Vieni
- Department of Diagnostic and Therapeutic Services, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Via Tricomi 5, 90127 Palermo, Italy
| | - Antonino Tuttolomondo
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Molecular and Clinical Medicine, University of Palermo, 90127 Palermo, Italy
| | - Anthony Yezzi
- Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA
| | - Albert Comelli
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
- National Biodiversity Future Center (NBFC), 90133 Palermo, Italy
| |
Collapse
|
14
|
Benabdallah N, Zhang H, Unnerstall R, Fears A, Summer L, Fassbender M, Rodgers BE, Abou D, Radchenko V, Thorek DLJ. Engineering a modular 44Ti/ 44Sc generator: eluate evaluation in preclinical models and estimation of human radiation dosimetry. EJNMMI Res 2023; 13:17. [PMID: 36853422 PMCID: PMC9975127 DOI: 10.1186/s13550-023-00968-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 02/19/2023] [Indexed: 03/01/2023] Open
Abstract
BACKGROUND 44Sc/47Sc is an attractive theranostic pair for targeted in vivo positron emission tomographic (PET) imaging and beta-particle treatment of cancer. The 44Ti/44Sc generator allows daily onsite production of this diagnostic isotope, which may provide an attractive alternative for PET facilities that lack in-house irradiation capabilities. Early animal and patient studies have demonstrated the utility of 44Sc. In our current study, we built and evaluated a novel clinical-scale 44Ti/44Sc generator, explored the pharmacokinetic profiles of 44ScCl3, [44Sc]-citrate and [44Sc]-NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid) in naïve mice, and estimated the radiation burden of 44ScCl3 in humans. METHODS 44Ti/44Sc (101.2 MBq) in 6 M HCl solution was utilized to assemble a modular ZR resin containing generator. After assembly, 44Sc was eluted with 0.05 M HCl for further PET imaging and biodistribution studies in female Swiss Webster mice. Based on the biodistribution data, absorbed doses of 44/47ScCl3 in human adults were calculated for 18 organs and tissues using the IDAC-Dose software. RESULTS 44Ti in 6 M HCl was loaded onto the organic resin generator with a yield of 99.97%. After loading and initial stabilization, 44ScCl3 was eluted with 0.05 M HCl in typical yields of 82.9 ± 5.3% (N = 16), which was normalized to the estimated generator capacity. Estimated generator capacity was computed based on elution time interval and the total amount of 44Ti loaded on the generator. Run in forward and reverse directions, the 44Sc/44Ti ratio from a primary column was significantly improved from 1038 ± 440 to 3557 ± 680 (Bq/Bq) when a secondary, replaceable, ZR resin cartridge was employed at the flow outlet. In vivo imaging and ex vivo distribution studies of the reversible modular generator for 44ScCl3, [44Sc]-citrate and [44Sc]-NODAGA show that free 44Sc remained in the circulation significantly longer than the chelated 44Sc. The dose estimation of 44ScCl3 reveals that the radiation burden is 0.146 mSv/MBq for a 70 kg adult male and 0.179 mSv/MBq for a 57 kg adult female. Liver, spleen and heart wall will receive the highest absorbed dose: 0.524, 0.502, and 0.303 mGy/MBq, respectively, for the adult male. CONCLUSIONS A clinical-scale 44Ti/44Sc generator system with a modular design was developed to supply 44ScCl3 in 0.05 M HCl, which is suitable for further radiolabeling and in vivo use. Our data demonstrated that free 44ScCl3 remained in the circulation for extended periods, which resulted in approximately 10 times greater radiation burden than stably chelated 44Sc. Stable 44Sc/47Sc-complexation will be more favorable for in vivo use and for clinical utility.
Collapse
Affiliation(s)
- Nadia Benabdallah
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO 63110 USA
| | - Hanwen Zhang
- Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO, 63110, USA. .,Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO, 63110, USA. .,Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO, 63110, USA.
| | - Ryan Unnerstall
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA
| | - Amanda Fears
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO 63110 USA
| | - Lucy Summer
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA
| | - Michael Fassbender
- grid.148313.c0000 0004 0428 3079Chemistry Division, Los Alamos National Laboratory, PO Box 1663, Los Alamos, NM 87545 USA
| | - Buck E. Rodgers
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA ,grid.516080.a0000 0004 0373 6443Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110 USA
| | - Diane Abou
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA ,grid.516080.a0000 0004 0373 6443Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Mallinckrodt Cyclotron Facility, Washington University School of Medicine, St. Louis, MO 63110 USA
| | - Valery Radchenko
- grid.232474.40000 0001 0705 9791Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3 Canada ,grid.17091.3e0000 0001 2288 9830Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1 Canada
| | - Daniel L. J. Thorek
- grid.4367.60000 0001 2355 7002Washington University School of Medicine, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Boulevard, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO 63110 USA ,grid.516080.a0000 0004 0373 6443Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO 63110 USA ,grid.4367.60000 0001 2355 7002Department of Biomedical Engineering, Washington University, St. Louis, MO 63110 USA
| |
Collapse
|
15
|
McLain DR, Brossard TW, De Kruijff R, Kankanamalage PHA, Rotsch DA. Evaluation of two extraction chromatography resins for scandium and titanium separation for medical isotope production. J Radioanal Nucl Chem 2023. [DOI: 10.1007/s10967-023-08783-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
|
16
|
Rizk HE, Breky MME, Attallah MF. Development of purification of no-carrier-added 47Sc of theranostic interest: selective separation study from the natTi(n,p) process. RADIOCHIM ACTA 2023. [DOI: 10.1515/ract-2022-0082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Abstract
Scandium-47 is one of the most promising medical radioisotopes, and its production and trace separation make it an attractive candidate for theranostic application. In this study, the production of no-carrier-added (NCA) 47Sc through the natTi(n,p) reaction and subsequent purification using liquid–liquid extraction was done for the theranostic application. The comparative separation of NCA 47Sc after the dissolution of an activated Ti target using Di-2-Ethylhexyl Phosphoric Acid (HDEHP) in kerosene was evaluated. The extraction process was optimized in terms of the concentration of extractant, extraction time, pH, and reaction temperature to achieve the maximum possible separation. HDEHP is efficient and promising for rapid extraction and separation of NCA 47Sc from Ti ions at low acidity (pH 0.85) with high extraction percent (>99%), contaminated with 22.3% of Ti ions after 5 min of extraction time. Different stripping reagents were used to separate loaded 47Sc and Ti ions. Firstly, 5 M HCl was enough for stripping the loaded Ti ions. Then the loaded 47Sc was separated with a purity of 100% using 0.05 M NaOH. The obtained results find the HDEHP a promising extractant for efficient separation of 47Sc from irradiated Ti target for preparing the 47Sc radiopharmaceuticals for theranostics applications.
Collapse
Affiliation(s)
- Hoda E. Rizk
- Nuclear Fuel Technology Department, Hot Laboratories and Waste Management Center , Egyptian Atomic Energy Authority , Cairo P.O. Box 13759 , Egypt
| | - Mohamed M. E. Breky
- Radiation Protection Department, Hot Laboratories and Waste Management Center , Egyptian Atomic Energy Authority, P.O. Box 13759 , Cairo , Egypt
| | - Mohamed F. Attallah
- Analytical Chemistry and Control Department, Hot Laboratories and Waste Management Center , Egyptian Atomic Energy Authority, P.O. Box 13759 , Cairo , Egypt
| |
Collapse
|
17
|
Li H, Luo Q, Zhang H, Ma X, Gu Z, Gong Q, Luo K. Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation. Chem Soc Rev 2023; 52:47-96. [PMID: 36427082 DOI: 10.1039/d2cs00437b] [Citation(s) in RCA: 15] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Cancer radio-immunotherapy, integrating external/internal radiation therapy with immuno-oncology treatments, emerges in the current management of cancer. A growing number of pre-clinical studies and clinical trials have recently validated the synergistic antitumor effect of radio-immunotherapy, far beyond the "abscopal effect", but it suffers from a low response rate and toxicity issues. To this end, nanomedicines with an optimized design have been introduced to improve cancer radio-immunotherapy. Specifically, these nanomedicines are elegantly prepared by incorporating tumor antigens, immuno- or radio-regulators, or biomarker-specific imaging agents into the corresponding optimized nanoformulations. Moreover, they contribute to inducing various biological effects, such as generating in situ vaccination, promoting immunogenic cell death, overcoming radiation resistance, reversing immunosuppression, as well as pre-stratifying patients and assessing therapeutic response or therapy-induced toxicity. Overall, this review aims to provide a comprehensive landscape of nanomedicine-assisted radio-immunotherapy. The underlying working principles and the corresponding design strategies for these nanomedicines are elaborated by following the concept of "from bench to clinic". Their state-of-the-art applications, concerns over their clinical translation, along with perspectives are covered.
Collapse
Affiliation(s)
- Haonan Li
- Department of Radiology, Department of Biotherapy, Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China.
| | - Qiang Luo
- Department of Radiology, Department of Biotherapy, Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China.
| | - Hu Zhang
- Amgen Bioprocessing Centre, Keck Graduate Institute, Claremont, CA 91711, USA
| | - Xuelei Ma
- Department of Radiology, Department of Biotherapy, Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China.
| | - Zhongwei Gu
- Department of Radiology, Department of Biotherapy, Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China.
| | - Qiyong Gong
- Department of Radiology, Department of Biotherapy, Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China. .,Functional and Molecular Imaging Key Laboratory of Sichuan Province and Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu 610041, China
| | - Kui Luo
- Department of Radiology, Department of Biotherapy, Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China. .,Functional and Molecular Imaging Key Laboratory of Sichuan Province and Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu 610041, China
| |
Collapse
|
18
|
Pallares RM, Abergel RJ. Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand? Front Med (Lausanne) 2022; 9:1020188. [PMID: 36619636 PMCID: PMC9812962 DOI: 10.3389/fmed.2022.1020188] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 12/05/2022] [Indexed: 12/24/2022] Open
Abstract
Targeted alpha therapy is an oncological treatment, where cytotoxic doses of alpha radiation are locally delivered to tumor cells, while the surrounding healthy tissue is minimally affected. This therapeutic strategy relies on radiopharmaceuticals made of medically relevant radionuclides chelated by ligands, and conjugated to targeting vectors, which promote the drug accumulation in tumor sites. This review discusses the state-of-the-art in the development of radiopharmaceuticals for targeted alpha therapy, breaking down their key structural components, such as radioisotope, targeting vector, and delivery formulation, and analyzing their pros and cons. Moreover, we discuss current drawbacks that are holding back targeted alpha therapy in the clinic, and identify ongoing strategies in field to overcome those issues, including radioisotope encapsulation in nanoformulations to prevent the release of the daughters. Lastly, we critically discuss potential opportunities the field holds, which may contribute to targeted alpha therapy becoming a gold standard treatment in oncology in the future.
Collapse
Affiliation(s)
- Roger M. Pallares
- Lawrence Berkeley National Laboratory, Chemical Sciences Division, Berkeley, CA, United States
| | - Rebecca J. Abergel
- Lawrence Berkeley National Laboratory, Chemical Sciences Division, Berkeley, CA, United States,Department of Nuclear Engineering, University of California, Berkeley, Berkeley, CA, United States,*Correspondence: Rebecca J. Abergel,
| |
Collapse
|
19
|
Rizk HE, Attallah MF, Ali AM. Lamellar structure silver sulfide nanoparticles for adsorption and selective separation of zirconium, yttrium and strontium ions. J DISPER SCI TECHNOL 2022. [DOI: 10.1080/01932691.2022.2151460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Hoda E. Rizk
- Nuclear Fuel Technology Department, Hot Laboratories Center, Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt
| | - Mohamed F. Attallah
- Analytical Chemistry and Control Department, Hot Laboratories Center, Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt
| | - Amal M. Ali
- Nuclear Fuel Technology Department, Hot Laboratories Center, Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt
| |
Collapse
|
20
|
Uddin MS, Basunia MS, Spahn I, Spellerberg S, Khan R, Uddin MM, Bernstein LA, Neumaier B, Qaim SM. Cross sections and calculated yields of some radionuclides of yttrium, strontium and rubidium formed in proton-induced reactions on enriched strontium-86: possibility of production of 85gSr, 83Rb and 82mRb in no-carrier-added form. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2022-0086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Abstract
Cross sections of the 86Sr(p,3n)84mY, 86Sr(p,αn)82mRb, and 86Sr(p,x)85gSr reactions were measured from their respective thresholds up to 16.2 MeV and from 23.0 to 44.1 MeV at FZJ, and from 14.3 to 24.5 MeV at LBNL, using 96.4% enriched 86SrCO3 as target material. Thin targets prepared by sedimentation were irradiated with protons in a stacked-form, and the induced radioactivity was measured by high-resolution γ-ray spectrometry. Nuclear model calculations based on the code TALYS reproduced our experimental cross section data well. From the excitation functions, the integral yields of the above three radionuclides were calculated. The yield of 85gSr via the natSr(n,γ) process was also measured using the TRIGA Mark-II reactor at AERE, Savar. A comparison of the reactor and cyclotron production of carrier-added 85gSr is given. The production possibilities of the three investigated radionuclides in no-carrier-added forms at a 30 MeV cyclotron via new routes are discussed.
Collapse
Affiliation(s)
- M. Shuza Uddin
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich , D-52425 Jülich , Germany
- Institute of Nuclear Science and Technology, Atomic Energy Research Establishment , Savar , Dhaka , Bangladesh
| | - M. Shamsuzzoha Basunia
- Nuclear Science Division, Lawrence Berkeley National Laboratory , Berkeley , CA 94720 , USA
| | - Ingo Spahn
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich , D-52425 Jülich , Germany
| | - Stefan Spellerberg
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich , D-52425 Jülich , Germany
| | - Rahat Khan
- Institute of Nuclear Science and Technology, Atomic Energy Research Establishment , Savar , Dhaka , Bangladesh
| | - M. Mezbah Uddin
- Centre for Research Reactor, Atomic Energy Research Establishment , Savar , Dhaka , Bangladesh
| | - Lee A. Bernstein
- Nuclear Science Division, Lawrence Berkeley National Laboratory , Berkeley , CA 94720 , USA
- Department of Nuclear Engineering, UC Berkeley , Berkeley , CA 94720 , USA
| | - Bernd Neumaier
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich , D-52425 Jülich , Germany
| | - Syed M. Qaim
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich , D-52425 Jülich , Germany
| |
Collapse
|
21
|
Abdelshafy MS, Ali BM, Elmageed KEA, Nafie HO, Hassan HE, Al-Abyad M. Study of activation cross sections of proton induced reactions on natBa and natCe near their threshold energy regions. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2022-0048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Abstract
Activation cross-sections of the nuclear reactions natBa(p,x)135,132gLa, 135mBa and natCe(p,x)142,139,138mPr, 141,139,137mCe have been measured experimentally at the MGC-20 cyclotron, Cairo, Egypt, from their respective threshold energies up to about 14.7 MeV. Stacked foil irradiation technique and high-resolution gamma-ray spectroscopy were used. A comparison between the experimental and theoretical data derived from the nuclear model codes EMPIRE and TALYS (in the form of the TENDL library) was performed. The agreement in the low-energy region is fairly good. Integral yields of the produced radioisotopes were estimated from the present cross-section data and the results are discussed in terms of their production possibilities.
Collapse
Affiliation(s)
| | - Bahaa Mohamed Ali
- Experimental Nuclear Physics Department , Cyclotron Facility, Nuclear Research Centre, Egyptian Atomic Energy Authority , Cairo 13759 , Egypt
| | | | - Hassan Omar Nafie
- Department of Physics , Faculty of Science, Benha University , Benha 13518 , Egypt
| | - H. Ebrahim Hassan
- Experimental Nuclear Physics Department , Cyclotron Facility, Nuclear Research Centre, Egyptian Atomic Energy Authority , Cairo 13759 , Egypt
| | - Mogahed Al-Abyad
- Experimental Nuclear Physics Department , Cyclotron Facility, Nuclear Research Centre, Egyptian Atomic Energy Authority , Cairo 13759 , Egypt
| |
Collapse
|
22
|
Exploring rapid chemical separations of Sc-47 produced from photonuclear reactions on natural vanadium targets. J Radioanal Nucl Chem 2022. [DOI: 10.1007/s10967-022-08611-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
23
|
Sadler AWE, Hogan L, Fraser B, Rendina LM. Cutting edge rare earth radiometals: prospects for cancer theranostics. EJNMMI Radiopharm Chem 2022; 7:21. [PMID: 36018527 PMCID: PMC9418400 DOI: 10.1186/s41181-022-00173-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Accepted: 07/22/2022] [Indexed: 11/10/2022] Open
Abstract
Background With recent advances in novel approaches to cancer therapy and imaging, the application of theranostic techniques in personalised medicine has emerged as a very promising avenue of research inquiry in recent years. Interest has been directed towards the theranostic potential of Rare Earth radiometals due to their closely related chemical properties which allow for their facile and interchangeable incorporation into identical bifunctional chelators or targeting biomolecules for use in a diverse range of cancer imaging and therapeutic applications without additional modification, i.e. a “one-size-fits-all” approach. This review will focus on recent progress and innovations in the area of Rare Earth radionuclides for theranostic applications by providing a detailed snapshot of their current state of production by means of nuclear reactions, subsequent promising theranostic capabilities in the clinic, as well as a discussion of factors that have impacted upon their progress through the theranostic drug development pipeline. Main body In light of this interest, a great deal of research has also been focussed towards certain under-utilised Rare Earth radionuclides with diverse and favourable decay characteristics which span the broad spectrum of most cancer imaging and therapeutic applications, with potential nuclides suitable for α-therapy (149Tb), β−-therapy (47Sc, 161Tb, 166Ho, 153Sm, 169Er, 149Pm, 143Pr, 170Tm), Auger electron (AE) therapy (161Tb, 135La, 165Er), positron emission tomography (43Sc, 44Sc, 149Tb, 152Tb, 132La, 133La), and single photon emission computed tomography (47Sc, 155Tb, 152Tb, 161Tb, 166Ho, 153Sm, 149Pm, 170Tm). For a number of the aforementioned radionuclides, their progression from ‘bench to bedside’ has been hamstrung by lack of availability due to production and purification methods requiring further optimisation. Conclusions In order to exploit the potential of these radionuclides, reliable and economical production and purification methods that provide the desired radionuclides in high yield and purity are required. With more reactors around the world being decommissioned in future, solutions to radionuclide production issues will likely be found in a greater focus on linear accelerator and cyclotron infrastructure and production methods, as well as mass separation methods. Recent progress towards the optimisation of these and other radionuclide production and purification methods has increased the feasibility of utilising Rare Earth radiometals in both preclinical and clinical settings, thereby placing them at the forefront of radiometals research for cancer theranostics.
Collapse
Affiliation(s)
| | - Leena Hogan
- ANSTO Life Sciences, Australian Nuclear Science and Technology Organisation (ANSTO), Kirrawee, NSW, 2232, Australia
| | - Benjamin Fraser
- ANSTO Life Sciences, Australian Nuclear Science and Technology Organisation (ANSTO), Kirrawee, NSW, 2232, Australia
| | - Louis M Rendina
- School of Chemistry, The University of Sydney, Sydney, NSW, 2006, Australia.
| |
Collapse
|
24
|
Production Review of Accelerator-Based Medical Isotopes. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27165294. [PMID: 36014532 PMCID: PMC9415084 DOI: 10.3390/molecules27165294] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/26/2022] [Revised: 08/15/2022] [Accepted: 08/16/2022] [Indexed: 11/17/2022]
Abstract
The production of reactor-based medical isotopes is fragile, which has meant supply shortages from time to time. This paper reviews alternative production methods in the form of cyclotrons, linear accelerators and neutron generators. Finally, the status of the production of medical isotopes in China is described.
Collapse
|
25
|
Pham TM, Duong VD, Doan VD, Vo VT, Le VT. Design synthesis of Y-90 glass microspheres and study of their therapeutic effects on mouse liver cancer cell line Hep3B. CHEMOSPHERE 2022; 299:134431. [PMID: 35358564 DOI: 10.1016/j.chemosphere.2022.134431] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Revised: 03/15/2022] [Accepted: 03/23/2022] [Indexed: 06/14/2023]
Abstract
In this article, a system for synthesizing Y-90 glass microspheres (Y-90-GM) was successfully designed in the Da Lat nuclear reactor (Vietnam), and the therapeutic effects of Y-90-GM on mice liver cancer cell line Hep3B were studied. The effects of synthesis factors, including heating time, heating temperature, gas flow rate, sample conduit length and diameter, were investigated to establish the optimal parameters. The size and shape of Y-90-GM were checked by field emission scanning electron microscope, and the radioactivity measurement was performed on a dosimeter. The results indicated that the optimal conditions for the synthesis of Y-90-GM were determined as the heating temperature of 1600 °C, heating time of 2 h, conduit length and diameter of 50 cm and 3.6 cm, and gas/oxygen flow rate of 15 mph. The Y-90-GM samples obtained at the optimal parameters have a size of 18-30 μm with a density of 3.53 g cm-3 and a specific radioactivity of 630 mCi g-1. The results of the therapeutic study on mice liver cancer cell line Hep3B showed that after two weeks of treatment with Y-90-GM (1mCi/mouse), the tumor volume was reduced by about 30.7% and after 3 consecutive treatment cycles, the liver cancer tumor was completely reduced. It was demonstrated that Y-90-GM is promising radiopharmaceuticals in the treatment of liver cancer by the radioembolization method.
Collapse
Affiliation(s)
- Thanh Minh Pham
- Center for Research and Production of Radioisotope, Dalat Nuclear Research Institute, 01 Nguyen Tu Luc, Dalat, 670000, Viet Nam
| | - Van Dong Duong
- Center for Research and Production of Radioisotope, Dalat Nuclear Research Institute, 01 Nguyen Tu Luc, Dalat, 670000, Viet Nam
| | - Van-Dat Doan
- The Faculty of Chemical Engineering, Industrial University of Ho Chi Minh City, Ho Chi Minh City, 70000, Viet Nam
| | - Van Thanh Vo
- Department of Human and Animal Physiology, Ho Chi Minh City University of Education, Ho Chi Minh City, 70000, Viet Nam
| | - Van Thuan Le
- Center for Advanced Chemistry, Institute of Research and Development, Duy Tan University, 03 Quang Trung, Da Nang, 55000, Viet Nam; The Faculty of Natural Sciences, Duy Tan University, 03 Quang Trung, Da Nang, 55000, Viet Nam.
| |
Collapse
|
26
|
Aldrich KE, Popov IA, Root HD, Batista ER, Greer SM, Kozimor SA, Lilley LM, Livshits MY, Mocko V, Janicke MT, Scott BL, Stein BW, Yang P. Synthesis, solid-state, solution, and theoretical characterization of an "in-cage" scandium-NOTA complex. Dalton Trans 2022; 51:9994-10005. [PMID: 35739082 DOI: 10.1039/d1dt03887g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Developing chelators that strongly and selectively bind rare-earth elements (Sc, Y, La, and lanthanides) represents a longstanding fundamental challenge in inorganic chemistry. Solving these challenges is becoming more important because of increasing use of rare-earth elements in numerous technologies, ranging from paramagnets to luminescent materials. Within this context, we interrogated the complexation chemistry of the scandium(III) (Sc3+) trication with the hexadentate 1,4,7-triazacyclononane-1,4,7-triacetic acid (H3NOTA) chelator. This H3NOTA chelator is often regarded as an underperformer for complexing Sc3+. A common assumption is that metalation does not fully encapsulate Sc3+ within the NOTA3- macrocycle, leaving Sc3+ on the periphery of the chelate and susceptible to demetalation. Herein, we developed a synthetic approach that contradicted those assumptions. We confirmed that our procedure forced Sc3+ into the NOTA3- binding pocket by using single crystal X-ray diffraction to determine the Na[Sc(NOTA)(OOCCH3)] structure. Density functional theory (DFT) and 45Sc nuclear magnetic resonance (NMR) spectroscopy showed Sc3+ encapsulation was retained when the crystals were dissolved. Solution-phase and DFT studies revealed that [Sc(NOTA)(OOCCH3)]1- could accommodate an additional H2O capping ligand. Thermodynamic properties associated with the Sc-OOCCH3 and Sc-H2O capping ligand interactions demonstrated that these capping ligands occupied critical roles in stabilizing the [Sc(NOTA)] chelation complex.
Collapse
Affiliation(s)
| | - Ivan A Popov
- Los Alamos National Laboratory, Los Alamos, NM, USA. .,Department of Chemistry, The University of Akron, Akron, Ohio 44325-3601, USA
| | | | | | | | | | | | | | | | | | - Brian L Scott
- Los Alamos National Laboratory, Los Alamos, NM, USA.
| | | | - Ping Yang
- Los Alamos National Laboratory, Los Alamos, NM, USA.
| |
Collapse
|
27
|
Bzowski P, Borys D, Gorczewski K, Chmura A, Daszewska K, Gorczewska I, Kastelik-Hryniewiecka A, Szydło M, d'Amico A, Sokół M. Efficiency of 124I radioisotope production from natural and enriched tellurium dioxide using 124Te(p,xn) 124I reaction. EJNMMI Phys 2022; 9:41. [PMID: 35666325 PMCID: PMC9170869 DOI: 10.1186/s40658-022-00471-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Accepted: 05/19/2022] [Indexed: 11/23/2022] Open
Abstract
Background 124I Iodine (T\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$_{1/2}$$\end{document}1/2 = 4.18 d) is the only long-life positron emitter radioisotope of iodine that may be used for both imaging and therapy as well as for 131I dosimetry. Its physical characteristics permits taking advantages of the higher Positron Emission Tomography (PET) image quality, whereas the availability of new molecules to be targeted with 124I makes it a novel innovative radiotracer probe for a specific molecular targeting. Results In this study Monte Carlo and SRIM/TRIM modelling was applied to predict the nuclear parameters of the 124I production process in a small medical cyclotron IBA 18/9 Cyclone. The simulation production yields for 124I and the polluting radioisotopes were calculated for the natural and enriched 124TeO2 + Al2O3 solid targets irradiated with 14.8 MeV protons. The proton beam was degraded energetically from 18 MeV with 0.2 mm Havar foil. The 124Te(p,xn)124I reactions were taken into account in the simulations. The optimal thickness of the target material was calculated using the SRIM/TRIM and Geant4 codes. The results of the simulations were compared with the experimental data obtained for the natural TeO2 +Al2O3 target. The dry distillation technique of the 124-iodine was applied. Conclusions The experimental efficiency for the natural Te target was better than 41% with an average thick target (>0.8 mm) yield of 1.32 MBq/μAh. Joining the Monte Carlo and experimental approaches makes it possible to optimize the methodology for the 124I production from the expensive Te enriched targets.
Collapse
Affiliation(s)
- Paweł Bzowski
- Department of Nuclear Medicine and Endocrine Oncology, PET Diagnostics Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.,Department of Systems Biology and Engineering, Silesian University of Technology, Akademicka 16, 44-100, Gliwice, Poland.,Biotechnology Center, Silesian University of Technology, Krzywoustego 8, 44-100, Gliwice, Poland
| | - Damian Borys
- Department of Nuclear Medicine and Endocrine Oncology, PET Diagnostics Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland. .,Department of Systems Biology and Engineering, Silesian University of Technology, Akademicka 16, 44-100, Gliwice, Poland. .,Biotechnology Center, Silesian University of Technology, Krzywoustego 8, 44-100, Gliwice, Poland.
| | - Kamil Gorczewski
- Department of Nuclear Medicine and Endocrine Oncology, PET Diagnostics Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | - Agnieszka Chmura
- Radiopharmacy and Preclinical PET Imaging Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | - Kinga Daszewska
- Radiopharmacy and Preclinical PET Imaging Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | - Izabela Gorczewska
- Department of Nuclear Medicine and Endocrine Oncology, PET Diagnostics Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | - Anna Kastelik-Hryniewiecka
- Radiopharmacy and Preclinical PET Imaging Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | - Marcin Szydło
- Radiopharmacy and Preclinical PET Imaging Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | - Andrea d'Amico
- Department of Nuclear Medicine and Endocrine Oncology, PET Diagnostics Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| | - Maria Sokół
- Department of Medical Physics, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
| |
Collapse
|
28
|
Nichols AL. Status of the decay data for medical radionuclides: existing and potential diagnostic γ emitters, diagnostic β + emitters and therapeutic radioisotopes. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2022-0004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Recommended half-lives and specific well-defined emission energies and absolute emission probabilities are important input parameters that should be well-defined to assist in ensuring the diagnostic and therapeutic efficacy of individual radionuclides when applied in the field of nuclear medicine. Bearing in mind the nature of these requirements, approximately one hundred radionuclides have been considered and re-assessed as to whether their decay data are either adequately quantified, or require further in-depth measurements to improve their existing status and merit full re-evaluations of their decay schemes. The primary aim of such a review is to provide sufficient information on the existing and future requirements for such atomic and nuclear data.
Collapse
Affiliation(s)
- Alan L. Nichols
- Department of Physics , University of Surrey , Guildford , GU2 7XH , UK
- Manipal Academy of Higher Education, Manipal, Karnataka 576104 , India
| |
Collapse
|
29
|
Lee JY, Chae JH, Hur MG, Yang SD, Kong YB, Lee J, Ju JS, Choi PS, Park JH. Theragnostic 64Cu/67Cu Radioisotopes Production With RFT-30 Cyclotron. Front Med (Lausanne) 2022; 9:889640. [PMID: 35665337 PMCID: PMC9158440 DOI: 10.3389/fmed.2022.889640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Accepted: 04/20/2022] [Indexed: 11/17/2022] Open
Abstract
64Cu and 67Cu are theragnostic pair radionuclides with promising application in the nuclear medicine. 64Cu is PET nuclide for the non-invasive diagnosis and 67Cu is beta emitter for therapy of various cancers. This study discusses optimization efforts in the production of these radioactive coppers carried out with 30 MeV cyclotron. Optimized conditions include target preparation, chemical separation, and quality control. The production routes of 64Cu and 67Cu were studied based on the nuclear reactions of 64Ni(p,n)64Cu and 70Zn(p,α)67Cu. The produced 64Cu and 67Cu have >99.9% of the radionuclidic purity. The yield at the end of bombardment (EOB) of 64Cu and 67Cu is 28.5 MBq/μAh and 67Cu is 0.58 MBq/μAh, respectively.
Collapse
|
30
|
Nuclear data for light charged particle induced production of emerging medical radionuclides. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2022-0011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Whatever the radionuclide to be used in nuclear medicine, it is essential to know the expected yield during the production process, but also of all the possible radionuclidic impurities coproduced, that can have an impact on the product final quality, as well as in the related waste management. The availability of the majority of emerging radioisotopes, including the theranostic ones or pairs, is mainly limited by the fact that, for most of them, the optimal production route still needs to be strengthened if not defined in some cases. The aim of this work is to present a review on the charged particle induced nuclear cross sections to produce some emerging radionuclides for medical applications to show that all types of projectiles should be considered in the quest of producing medical radionuclides. An accurate analysis of the production routes is presented for some radionuclides (67Cu, 47Sc, 89Zr, 103Pd, 186gRe, 97Ru, 211At) chosen as examples to highlight (i) how the quality of the final product strongly depends on the chosen target/projectile/energy parameters set, (ii) how deuteron production routes may sometimes be more effective than the proton ones or lead to a different impurity profile and (iii) how α-particle beams may allow to bypass the limitations occurring when using Z = 1 beams. An overview of possible advantages and drawbacks of the cited production routes and of potential cross sections that still need to be measured, is also reported.
Collapse
|
31
|
Production of neutron deficient rare earth radionuclides by heavy ion activation. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2022-0018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
The attempts to produce neutron deficient radioisotopes of rare Earth elements by heavy ion activation are discussed in this review. The heavy ion induced reaction products have large atomic number difference with that of the target; therefore, radiochemical separation of no-carrier-added radio-lanthanides from the target matrix becomes easier. Heavy ion induced reactions also allow the production of rare Earth radionuclides from non-rare Earth target by tailor-made target-projectile combinations, and in those cases, radiochemical separations become even more easier. In general, the cross sections of heavy ion induced reactions are less than those of light charged particle induced reactions. However, some of the heavy ion induced reactions have comparable cross sections with those of light ion induced reactions. The range of heavy ions is also much smaller in the target matrix than that of lighter charged particles. These points hinder application of heavy ion induced reactions to produce radionuclides for nuclear medicine.
Collapse
|
32
|
Qaim SM, Spahn I, Scholten B, Spellerberg S, Neumaier B. The role of chemistry in accelerator-based production and separation of radionuclides as basis for radiolabelled compounds for medical applications. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2022-0017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Radiochemical separations used in large scale routine production of diagnostic and therapeutic radionuclides at a particle accelerator for patient care are briefly outlined. The role of chemistry at various stages of development of a production route of a novel radionuclide, namely nuclear data measurement, high-current targetry, chemical processing and quality control of the product, is discussed in detail. Special attention is paid to production of non-standard positron emitters (e.g. 44gSc, 64Cu, 68Ga, etc.) at a cyclotron and novel therapeutic radionuclides (e.g. 67Cu, 225Ac, etc.) at an accelerator. Some typical examples of radiochemical methods involved are presented.
Collapse
Affiliation(s)
- Syed M. Qaim
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Ingo Spahn
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Bernhard Scholten
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Stefan Spellerberg
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| | - Bernd Neumaier
- Institut für Neurowissenschaften und Medizin: INM-5 (Nuklearchemie), Forschungszentrum Jülich GmbH , D-52425 Jülich , Germany
| |
Collapse
|
33
|
Al-Abyad M, Hassan HE, Mohamed GY, Saleh ZA, Comsan MNH, Azzam A. Nuclear reaction data for medical and industrial applications: recent contributions by Egyptian cyclotron group. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2021-1118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Abstract
Measurement and evaluation of nuclear data of radioisotopes used as tracers are continuously underway in many laboratories to reach high accuracy for their use in production. We briefly mention some of the radionuclides useful for medical diagnostics and other industrial applications. The research group at the Egyptian cyclotron facility (EGCF) performed in collaboration with nuclear research centres and universities in many countries (Germany, Hungary, Finland, USA, Japan and Saudi Arabia) some measurements and evaluations of interesting nuclear reaction data. Nuclear reactions induced by p, d and α-particles on a wide variety of targets were extensively studied from threshold energy up to 50 MeV. Nuclear model code calculations, mainly using EMPIRE and TALYS, were performed for nuclear data validation. Proton and neutron activation of some industrially interesting samples were also studied as technological application of nuclear analytical techniques. Since the cyclotron facility is dedicated to development of the production routes of medical radioisotopes, this overview presents examples of optimization experiments to establish good production conditions.
Collapse
Affiliation(s)
- Mogahed Al-Abyad
- Cyclotron Facility, Nuclear Physics Department , Nuclear Research Center, Egyptian Atomic Energy Authority , Cairo 13759 , Egypt
- Nuclear Physics Department , Nuclear Research Center, Egyptian Atomic Energy Authority , Cairo 13759 , Egypt
| | - H. Ebrahim Hassan
- Cyclotron Facility, Nuclear Physics Department , Nuclear Research Center, Egyptian Atomic Energy Authority , Cairo 13759 , Egypt
| | - Gehan Y. Mohamed
- Nuclear Physics Department , Nuclear Research Center, Egyptian Atomic Energy Authority , Cairo 13759 , Egypt
| | - Zeinab A. Saleh
- Nuclear Physics Department , Nuclear Research Center, Egyptian Atomic Energy Authority , Cairo 13759 , Egypt
| | - M. Nassef H. Comsan
- Nuclear Physics Department , Nuclear Research Center, Egyptian Atomic Energy Authority , Cairo 13759 , Egypt
| | - Ahmed Azzam
- Nuclear Physics Department , Nuclear Research Center, Egyptian Atomic Energy Authority , Cairo 13759 , Egypt
| |
Collapse
|
34
|
An overview of nuclear data standardisation work for accelerator-based production of medical radionuclides in Pakistan. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2022-0012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Abstract
The standardisation of nuclear reaction cross section data is an integral part of optimisation of production routes of medical radionuclides. The production cross sections are available for the reactor and cyclotron produced radionuclides to be used for diagnostics or therapeutic procedures. The types of nuclear data needed, and the sources of their availability are summarized. The method of standardisation of charged-particle data is briefly described. A historical overview of research work in Pakistan in this direction is given. Examples of a few medically important radionuclides, such as 64Cu, 86Y, 89Zr, 103Pd, 186Re, etc., whose data were standardised and evaluated are highlighted. Calculated thick target yields from the recommended data are given. Some new directions in the nuclear data research are outlined.
Collapse
|
35
|
Kazakov AG, Babenya JS, Ivanova MK, Vinokurov SE, Myasoedov BF. Study of 90Y Sorption with Nanodiamonds as Potential Carriers in the Radiopharmaceutical Composition. RADIOCHEMISTRY 2022. [DOI: 10.1134/s1066362222010076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
36
|
Attallah MF, Mohamed GY, Breky MME. Production and subsequent separation of 47Sc of nuclear medicine applications using neutron-induced reactions on different natural targets. J Radioanal Nucl Chem 2022. [DOI: 10.1007/s10967-022-08232-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Abstract47Sc can be produced from different three neutron induced nuclear reactions as 47Ti(n,p)47Sc, 50V(n,α)47Sc and 46Ca(n,γ)47Ca, 47Ca(β−)47Sc using the Egyptian Second Research Reactor. The measured neutron cross-sections (σ) are 62.12 ± 1.93, 4.51 ± 1.27 and 69.36 ± 2.01 mb from the natural targets of TiO2, V2O3 and CaO respectively. The carrier-free 47Sc from 47Ti(n,p), was purified using a composite of Alginate–Carboxymethyl cellulose/di-2-ethylhexyl phosphoric acid. The radiochemical separation of 47Sc with a recovery yield of 90 ± 1.2% was obtained. The eluted 47Sc passed quality control tests (chemical, radionuclide, and radiochemical purities) and was found to be suitable for nuclear medicine applications.
Collapse
|
37
|
Fan FL, Li HW, Cheng NW, Huang QG, Chen DS, Wu XL, Qin Z. Selective adsorption and separation of Cu(II) from Zn solution by CU resin. J Radioanal Nucl Chem 2022. [DOI: 10.1007/s10967-022-08191-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
38
|
Positron Emission Intensity in the Decay of 86gY for Use in Dosimetry Studies. Molecules 2022; 27:molecules27030768. [PMID: 35164033 PMCID: PMC8839740 DOI: 10.3390/molecules27030768] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 01/11/2022] [Accepted: 01/17/2022] [Indexed: 11/16/2022] Open
Abstract
The β+-emitting radionuclide 86gY (t1/2 = 14.7 h) forms a matched-pair with the β−-emitting therapeutic radionuclide 90Y (t1/2 = 2.7 d) for theranostic application in medicine. This approach demands a precise knowledge of the positron emission probability of the PET nuclide which was until recently rather uncertain for 86gY. In this work, an 86gY source of high radionuclidic purity was prepared and a direct measurement of the positron emission intensity per 100 decay of the parent (hereafter “positron emission intensity”) was performed using high-resolution HPGe detector γ-ray spectroscopy. The electron capture intensity was also determined as an additional check by measuring the Kα and Kβ X-rays of energies 14.1 and 15.8 keV, respectively, using a low energy HPGe detector. From those measurements, normalized values of 27.2 ± 2.0% for β+-emission and 72.8 ± 2.0% for EC were obtained. These results are in excellent agreement with values recently reported in the literature based on a detailed decay scheme study.
Collapse
|
39
|
Müller C, Schibli R, Bernhardt P, Köster U, van der Meulen NP. Terbium radionuclides for theranostics. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00076-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
40
|
Theranostic radiopharmacy for the nuclear medicine and molecular imaging. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00066-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
41
|
van der Meulen NP, Talip Z. Non-conventional radionuclides: The pursuit for perfection. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00052-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
42
|
Barca C, Griessinger CM, Faust A, Depke D, Essler M, Windhorst AD, Devoogdt N, Brindle KM, Schäfers M, Zinnhardt B, Jacobs AH. Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy. Pharmaceuticals (Basel) 2021; 15:13. [PMID: 35056071 PMCID: PMC8780589 DOI: 10.3390/ph15010013] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 12/16/2021] [Accepted: 12/16/2021] [Indexed: 02/06/2023] Open
Abstract
Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the definition of theranostics was initially restricted to a single compound allowing visualization and therapy simultaneously, the concept has been widened with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. Here, we review the clinical applications of different theranostic radiopharmaceuticals in managing different tumor types (differentiated thyroid, neuroendocrine prostate, and breast cancer) that support the combination of innovative oncological therapies such as gene and cell-based therapies with RT.
Collapse
Affiliation(s)
- Cristina Barca
- European Institute for Molecular Imaging, University of Münster, D-48149 Münster, Germany; (A.F.); (D.D.); (M.S.); (B.Z.)
| | - Christoph M. Griessinger
- Roche Innovation Center, Early Clinical Development Oncology, Roche Pharmaceutical Research and Early Development, CH-4070 Basel, Switzerland;
| | - Andreas Faust
- European Institute for Molecular Imaging, University of Münster, D-48149 Münster, Germany; (A.F.); (D.D.); (M.S.); (B.Z.)
- Department of Nuclear Medicine, University Hospital Münster, D-48149 Münster, Germany
| | - Dominic Depke
- European Institute for Molecular Imaging, University of Münster, D-48149 Münster, Germany; (A.F.); (D.D.); (M.S.); (B.Z.)
| | - Markus Essler
- Department of Nuclear Medicine, University Hospital Bonn, D-53127 Bonn, Germany;
| | - Albert D. Windhorst
- Department Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands;
| | - Nick Devoogdt
- In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, B-1090 Brussel, Belgium;
| | - Kevin M. Brindle
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 ORE, UK;
| | - Michael Schäfers
- European Institute for Molecular Imaging, University of Münster, D-48149 Münster, Germany; (A.F.); (D.D.); (M.S.); (B.Z.)
- Department of Nuclear Medicine, University Hospital Münster, D-48149 Münster, Germany
| | - Bastian Zinnhardt
- European Institute for Molecular Imaging, University of Münster, D-48149 Münster, Germany; (A.F.); (D.D.); (M.S.); (B.Z.)
- Department of Nuclear Medicine, University Hospital Münster, D-48149 Münster, Germany
- Biomarkers and Translational Technologies, Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Andreas H. Jacobs
- European Institute for Molecular Imaging, University of Münster, D-48149 Münster, Germany; (A.F.); (D.D.); (M.S.); (B.Z.)
- Department of Geriatrics and Neurology, Johanniter Hospital, D-53113 Bonn, Germany
- Centre of Integrated Oncology, University Hospital Bonn, D-53127 Bonn, Germany
| |
Collapse
|
43
|
Koziorowski J, Ballinger J. Theragnostic radionuclides: a clinical perspective. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF... 2021; 65:306-314. [PMID: 34881851 DOI: 10.23736/s1824-4785.21.03424-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The concept of theragnostics goes back to the earliest days of nuclear medicine, with [123I/131I]iodide in thyroid disease and [123I/131I]MIBG in phaeochromocytoma being examples in long-term use. However, in recent years there has been a great expansion in the application of theragnostics, beginning with [68Ga/177Lu]-labelled somatostatin peptides for evaluation and treatment of neuroendocrine tumors. We are currently seeing the rapid development of [68Ga/177Lu]PSMA theragnostics in metastatic prostate cancer. While these applications are very promising, there are a number of practicalities which must be addressed in the development and introduction of novel theragnostics. The physical half-lives of the diagnostic and therapeutic radionuclides must be appropriate for imaging and delivery of targeted cell killing, respectively. The types of radioactive emissions are critical; beta particles can traverse several millimeters but also risk damaging non-target tissues, while alpha particles deliver their energy over a much shorter path length, a few cell diameters, and must be more directly targeted. It must be practical to produce the therapeutic radionuclide and the final radiopharmaceutical and deliver them to the final user within an appropriate time-frame determined by half-life and stability. The biodistribution of the agent must demonstrate adequate accumulation and retention in the target tissue with clearance from adjacent and/or radio-sensitive normal tissues. The commercial success of recently introduced theragnostics suggests a rosy future for personalized medicine.
Collapse
|
44
|
Ghosh K, Naskar N, Lahiri S. Separation of ultra-trace amount of 44mSc from α-particle activated KBr target. J Radioanal Nucl Chem 2021. [DOI: 10.1007/s10967-021-08088-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
45
|
Snow MS, Foley A, Ward JL, Kinlaw MT, Stoner J, Carney KP. High purity 47Sc production using high-energy photons and natural vanadium targets. Appl Radiat Isot 2021; 178:109934. [PMID: 34598038 DOI: 10.1016/j.apradiso.2021.109934] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 08/19/2021] [Accepted: 09/02/2021] [Indexed: 11/16/2022]
Abstract
Scandium-47 (47Sc) is of high value for targeted radiotherapy and theranostics; we report a novel, cost-effective approach to produce high-purity 47Sc via photonuclear reactions with natural vanadium. Irradiation at 20 MeV photon end-point energy produces >99.998% pure 47Sc, while irradiation at 38 MeV produces 98.8 ± 1.6% pure 47Sc. Experimental data suggest producing greater than 100 mCi (3700 MBq) of 47Sc using this approach may be feasible. Future research into refinement and scale-up to support pre-clinical research is recommended.
Collapse
Affiliation(s)
- Mathew S Snow
- Idaho National Laboratory, 1765 N. Yellowstone Hwy, Idaho Falls, ID, 83415. USA.
| | - Ari Foley
- Idaho National Laboratory, 1765 N. Yellowstone Hwy, Idaho Falls, ID, 83415. USA
| | - Jessica L Ward
- Idaho National Laboratory, 1765 N. Yellowstone Hwy, Idaho Falls, ID, 83415. USA
| | - Mathew T Kinlaw
- Idaho National Laboratory, 1765 N. Yellowstone Hwy, Idaho Falls, ID, 83415. USA
| | - Jon Stoner
- Idaho Accelerator Center, 1500 Alvin Ricken Drive, Pocatello, ID, 83201, USA
| | - Kevin P Carney
- Idaho National Laboratory, 1765 N. Yellowstone Hwy, Idaho Falls, ID, 83415. USA
| |
Collapse
|
46
|
Mausolf EJ, Johnstone EV, Mayordomo N, Williams DL, Guan EYZ, Gary CK. Fusion-Based Neutron Generator Production of Tc-99m and Tc-101: A Prospective Avenue to Technetium Theranostics. Pharmaceuticals (Basel) 2021; 14:ph14090875. [PMID: 34577575 PMCID: PMC8467155 DOI: 10.3390/ph14090875] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Revised: 08/20/2021] [Accepted: 08/26/2021] [Indexed: 12/14/2022] Open
Abstract
Presented are the results of 99mTc and 101Tc production via neutron irradiation of natural isotopic molybdenum (Mo) with epithermal/resonance neutrons. Neutrons were produced using a deuterium-deuterium (D-D) neutron generator with an output of 2 × 1010 n/s. The separation of Tc from an irradiated source of bulk, low-specific activity (LSA) Mo on activated carbon (AC) was demonstrated. The yields of 99mTc and 101Tc, together with their potential use in medical single-photon emission computed tomography (SPECT) procedures, have been evaluated from the perspective of commercial production, with a patient dose consisting of 740 MBq (20 mCi) of 99mTc. The number of neutron generators to meet the annual 40,000,000 world-wide procedures is estimated for each imaging modality: 99mTc versus 101Tc, D-D versus deuterium-tritium (D-T) neutron generator system outputs, and whether or not natural molybdenum or enriched targets are used for production. The financial implications for neutron generator production of these isotopes is also presented. The use of 101Tc as a diagnostic, therapeutic, and/or theranostic isotope for use in medical applications is proposed and compared to known commercial nuclear diagnostic and therapeutic isotopes.
Collapse
Affiliation(s)
| | - Erik V. Johnstone
- Innovative Fuel Solutions LLC, North Las Vegas, NV 89031, USA;
- Correspondence:
| | - Natalia Mayordomo
- Helmholtz-Zentrum Dresden–Rossendorf (HZDR), Institute of Resource Ecology, Bautzner Landstraße 400, 01328 Dresden, Germany;
| | - David L. Williams
- Adelphi Technology, Inc., Redwood City, CA 94063, USA; (D.L.W.); (E.Y.Z.G.); (C.K.G.)
| | - Eugene Yao Z. Guan
- Adelphi Technology, Inc., Redwood City, CA 94063, USA; (D.L.W.); (E.Y.Z.G.); (C.K.G.)
| | - Charles K. Gary
- Adelphi Technology, Inc., Redwood City, CA 94063, USA; (D.L.W.); (E.Y.Z.G.); (C.K.G.)
| |
Collapse
|
47
|
Sneddon D, Cornelissen B. Emerging chelators for nuclear imaging. Curr Opin Chem Biol 2021; 63:152-162. [PMID: 34051509 DOI: 10.1016/j.cbpa.2021.03.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 02/28/2021] [Accepted: 03/09/2021] [Indexed: 11/25/2022]
Abstract
Chelators are necessary in nuclear medicine imaging to direct an inorganic radionuclide, a radiometal, to a desired target; unfortunately, there is no 'one-size-fits-all' chelator. As the toolbox of radiometals is expanding, new chelators are required to prevent off-target side effects. 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is the current gold standard chelator for several radiometals, but typically, chelation requires harsh conditions, making it unsuitable to label biological vectors. The ideal chelator would allow labelling under mild conditions (near-neutral pH and low temperatures [∼37 °C]) and be both thermodynamically and kinetically stable. Over the past 2-3 years, several exciting chelators have been developed that have superior properties to make them worth investigating for future clinical applications.
Collapse
Affiliation(s)
- Deborah Sneddon
- MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 7LE, United Kingdom.
| | - Bart Cornelissen
- MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 7LE, United Kingdom
| |
Collapse
|
48
|
Naskar N, Lahiri S. Separation of 71,72As from alpha particle induced gallium oxide target by solid cation and anion exchangers, DOWEX-50 and DOWEX-1. Appl Radiat Isot 2021; 176:109876. [PMID: 34330034 DOI: 10.1016/j.apradiso.2021.109876] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 06/28/2021] [Accepted: 07/20/2021] [Indexed: 11/26/2022]
Abstract
46.0 MeV alpha particle induced reaction on gallium oxide target results production of no-carrier-added (NCA) 71,72As and 67Ga tracer. 71,72As were separated from the target matrix by solid liquid extraction (SLX) using two different exchangers, Dowex-1 and Dowex-50. At best condition of 0.2 g Dowex-1 + 6 M HCl and 0.2 g Dowex-50 + 10-3 M HCl bulk gallium was completely extracted leaving behind NCA 71,72As in the aqueous phase. Dowex-50 was found to be more suitable and offered high separation factor, 3.2 × 105.
Collapse
Affiliation(s)
- Nabanita Naskar
- Saha Institute of Nuclear Physics, 1/AF Bidhannagar, Kolkata, 700064, India
| | - Susanta Lahiri
- Saha Institute of Nuclear Physics, 1/AF Bidhannagar, Kolkata, 700064, India; Homi Bhabha National Institute, Anushakti Nagar, Mumbai, 400094, India.
| |
Collapse
|
49
|
Gizawy MA, Shamsel-Din HA, Attallah MF. Purification development of carrier-free 47Sc produced from natTi(n,p) reaction for radiotheranostic applications. J Radioanal Nucl Chem 2021. [DOI: 10.1007/s10967-021-07745-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
50
|
Naskar N, Lahiri S. Theranostic Terbium Radioisotopes: Challenges in Production for Clinical Application. Front Med (Lausanne) 2021; 8:675014. [PMID: 34136508 PMCID: PMC8200528 DOI: 10.3389/fmed.2021.675014] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 04/06/2021] [Indexed: 12/19/2022] Open
Abstract
Currently, research on terbium has gained a momentum owing to its four short-lived radioisotopes, 149Tb, 152Tb, 155Tb, and 161Tb, all of which can be considered in one or another field of nuclear medicine. The members of this emerging quadruplet family have appealing nuclear characteristics and have the potential to do justice to the proposed theory of theranostics nuclear medicine, which amalgamates therapeutic and diagnostic radioisotopes together. The main challenge for in vivo use of these radioisotopes is to produce them in sufficient quantity. This review discusses that, at present, neither light charged particle nor the heavy ion (HI) activation are suitable for large-scale production of neutron deficient terbium nuclides. Three technological factors like (i) enrichment of stable isotopes to a considerable level, (ii) non-availability of higher energies in commercial cyclotrons, and (iii) non-availability of the isotope separation technique coupled with commercial accelerators limit the large scale production of terbium radionuclides by light charged particle activation. If in future, the technology can overcome these hurdles, then the light charged particle activation of enriched targets would produce a high amount of useful terbium radionuclides. On the other hand, to date, the spallation reaction coupled with an online isotope separator has been found suitable for such a requirement, which has been adopted by the CERN MEDICIS programme. The therapeutic 161Tb radionuclide can be produced in a reactor by neutron bombardment on enriched 160Gd target to produce 161Gd which subsequently decays to 161Tb. The radiochemical separation is mandatory even if the ISOL technique is used to obtain high radioisotopic purity of the desired radioisotope.
Collapse
Affiliation(s)
- Nabanita Naskar
- Chemical Sciences Duvision, Saha Institute of Nuclear Physics, Kolkata, India
| | - Susanta Lahiri
- Chemical Sciences Duvision, Saha Institute of Nuclear Physics, Kolkata, India
| |
Collapse
|